Mirum is developing IBAT inhibitor treatments for rare liver diseases impacting children and adults. LIVMARLI is approved in the US for cholestatic pruritus in patients with ALGS one year of age and older. It is being studied in PFIC and BA. Volixibat is being evaluated for ICP, PSC, and PBC.